Platelet-derived growth factor-BB (PDGF-BB), one of the therapeutic targets for endothelial dysfunction of the BBB, can bind to the PDGFβ receptor (PDGFRβ) and activate phosphatidylinositol-4,5-diphosphate 3-kinase/protein kinase B (PI3K/Akt), which is involved in neuroprotection against cerebral ischemic injury (Zheng et al., 2019). This evidence concerns the gene AKT1 and endothelial dysfunction.